 "Sun Pharma gains on USFDA nod for psoriasis drug Ilumya")
Sun Pharmaceuticals Industries was up 3% at Rs 522 on the BSE in early morning trade after the company on Wednesday post market hours announced US Food and Drug Administration (USFDA) approval for psoriasis drug Ilumya, its first biologic drug in the market.
The FDA approval of Ilumya for the treatment of adults with moderate-to-severe plaque psoriasis was supported by data from the pivotal Phase-3 reSURFACE clinical development program, Sun Pharma said in a press release.
The market for psoriasis drugs in US is over $ 6 billion and the approval allows the drug maker to expand its portfolio in dermatology space. Biologic drugs are made from living cells.
“With the approval of Ilumya and our long-standing commitment in dermatology we are focused on making a difference for people living with moderate-to-severe plaque psoriasis,” said Abhay Gandhi, president and chief executive officer, North America, Sun Pharma.
At 09:17 am; the stock was trading 2% higher at Rs 515 as compared to a marginal 0.05% gain in the S&P BSE Sensex. A combined around one million shares changed hands on the counter on the BSE and NSE.
In past one year, Sun Pharma has underperformed the market by falling 26% against 12% rise in the benchmark index.
The FDA approval of Ilumya for the treatment of adults with moderate-to-severe plaque psoriasis was supported by data from the pivotal Phase-3 reSURFACE clinical development program, Sun Pharma said in a press release.
The market for psoriasis drugs in US is over $ 6 billion and the approval allows the drug maker to expand its portfolio in dermatology space. Biologic drugs are made from living cells.
“With the approval of Ilumya and our long-standing commitment in dermatology we are focused on making a difference for people living with moderate-to-severe plaque psoriasis,” said Abhay Gandhi, president and chief executive officer, North America, Sun Pharma.
At 09:17 am; the stock was trading 2% higher at Rs 515 as compared to a marginal 0.05% gain in the S&P BSE Sensex. A combined around one million shares changed hands on the counter on the BSE and NSE.
In past one year, Sun Pharma has underperformed the market by falling 26% against 12% rise in the benchmark index.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%